Tuesday, 15th November Joint 2016 COSA and ANZBCTG Annual Scientific Meeting

Content: In this interactive breakfast session invited international speaker, Professor Melinda Irwin from Yale School of Public Health, will discuss current and future opportunities and challenges in physical activity and cancer research and clinical care. Prof Irwin is a prominent leader in the field of physical activity and cancer risk and mortality. Her research over the past 15 years has focused on randomized trials of exercise and weight loss on biological markers, treatment side effects and quality of life in cancer patients and survivors.

Speaker: Melinda Irwin

Content: This breakfast symposium will provide attendees with insights into breakthrough cancer pain: the definition of breakthrough cancer pain, how its management is evolving and what this means for the doctor, the palliative care team and the patient. Professor Richard Chye, Palliative Care specialist at St Vincent’s Hospital, Sydney, will share his knowledge relating to the management of breakthrough cancer pain. A patient will also discuss the impact of effective breakthrough cancer pain management on his quality of life. There will be time for questions and discussion.

Speaker: Professor Ricahrd Chye Director, Sacred Heart Supportive & Palliative Care St Vincent’s Hospital Sydney, NSW

This breakfast symposium will give attendees insights into the practical aspects of proactively managing everolimus-induced stomatitis In the recently reported SWISH clinical trial, prophylactic use of a dexamethasone solution as a mouthwash four times daily for the first 8 weeks of treatment significantly reduced the incidence of everolimus-induced stomatitis1. In the light of the SWISH trial outcome, this session will discuss the practicalities of managing everolimus-associated stomatitis in Australia with two real-world perspectives. Dr Lina Pugliano will review the SWISH trial data and then discuss her experiences and give her insights into prophylactically managing everolimus-related stomatitis. Pharmacist Obaid Fazli will outline different approaches to supplying everolimus patients with steroidal mouthwash that are currently being practised in Australia, highlighting the practical benefits and limits of these.

1Rugo, HS, J Clin Oncol 34, 2016 (suppl; abstr 525)

Speakers: 
Dr Lina Pugliano, Medical Oncologist Northern Cancer Institute (NCI) St Leonards, Sydney, NSW 
SWISH trial recap: using prophylactic steroidal mouthwash to control everolimus-associated stomatitis 

Obaid Fazli, Assistant Deputy Director and Senior Oncology Pharmacist, Monash Health-Moorabbin Pharmacy Department, Melbourne, Victoria 
Putting SWISH into practice: adapting SWISH to the Australian setting 

Welcome by COSA President

Welcome to Country by local Indigenous group

Official opening by His Excellency the Honorable Paul de Jersey AC, Governor of Queensland

• Breast Cancer in 2016: where to from here? - Shom Goel
• The evolving role of surgeons and surgery in breast cancer management - Laura Esserman
• Critical decision making in Radiation Therapy for breast cancer - Boon Chua
• Global issues in breast cancer survivorship - Deborah Fenlon

• Advances in the Management of HER2-Positive Breast Cancer - Shom Goel
• Challenges with the Implementation into Clinical Practice of Subcutaneous Trastuzumab – A Pharmacist’s Perspective - Geeta Sandhu
• Nursing Care of the Breast Cancer Patient with Targeted Therapy-Related Side Effects - Jenny Gilchrist
• Overview of current therapeutic trials in Australia - Nicholas Wilcken

• Surgical Aspects of Brain Metastases and Avoiding Complications - Sarah Olson
• Changing paradigms in the management of brain metastases - Matthew Foote
• Brain metastases: Management and Issues - From Oncology and Palliative Care Perspectives - Sylvia Lee
• Targeting HER receptors in Brain Metastases - Sunil R Lakhani

• Exercise in the Management of Arthralgia - Melinda Irwin
• Exercise for the management of upper-body morbidity - Sandi C Hayes
• Exercise for the management of fatigue  - Carolina Sandler
• Exercise for the management of distress and cognitive impairment - Haryana Dhillon

• A 12 year population study of Ductal Carcinoma Insitu (DCIS): incidence, tumour characteristics and breast cancer recurrence in Queensland women - Nathan Dunn
• Chemotherapy for early breast cancer in patients with comorbidity: a systematic review and meta-analysis - Melissa Edwards
• Burden of colorectal cancer in Australia attributable to lifestyle-related risk factors - Maarit A Laaksonen
•   A life course approach to exposure to stressful life events and risk of major depressive symptoms in women after cancer: Results from the Australian Women’s Wellness After Cancer Program (WWACP) - Charrlotte Seib
• Place of death in patients with advanced NSCLC in South Western Sydney. - Rebecca Strutt
• Contrasting temporal trends in lung cancer incidence by socioeconomic status among women in Australia, 1985-2009   - Xue Qin Yu

• Immunotherapy directions in breast cancer - Sherene Loi
• Management of Immunotherapy Toxicity - Alexander Menzies
• Immunotherapies- The pharmacist's perspective - Christine Carrington
• Immunotherapy - The future - Ken O'Byrne

• Ki67/BCL2 index: impact on prognosis in Australian women - Alice RT Bergin
• Treatment of TSC1-deleted high-grade serous ovarian cancer confounded by Hedgehog pathway over-expression - Gwo Yaw Ho
• Translation of the CROSS tri-modality protocol for oesophageal cancer to the general population: A compliance audit. - Mahnoor Mian
• Can we “Starve Cancer Cells to Death” with Selective PARP14 Inhibitors? - Stephanie S Schweiker
• The impact of a Mediterranean-style dietary pattern on cancer-related fatigue and quality of life in men with prostate cancer treated with androgen deprivation therapy: A pilot study - Brenton J Baguley
• Long-term Outcomes With Nivolumab vs Docetaxel in Patients With Advanced NSCLC: CheckMate 017 and CheckMate 057 2-year Update - Fabrice Barlesi
• A Retrospective Audit of End-of-Life Care in Oncology Patients at The Canberra Hospital - Monique Batten
• Efficacy and safety of enzalutamide versus bicalutamide in younger and older patients with metastatic castration-resistant prostate cancer in the TERRAIN trial - Scott Brown
• Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients with advanced melanoma (MEL) - Jonathan Cebon
• Prognostic significance of baseline blood results for patients with stage IV non-small cell lung cancer (NSCLC) treated in South Western Sydney - Clement Chao
• Pembrolizumab for metastatic melanoma in renal allograft recipient with subsequent graft rejection and treatment response failure, a case report - Michail Charakidis
• Nivolumab in previously treated Advanced Non-small Cell Lung Cancer- Calvary Mater Newcastle (CMN) Experience - Elizabeth Connolly
• Microwave ablation versus Radiofrequency ablation for Hepatocellular Carcinoma: a Systematic Review and Meta-analysis of Randomised Controlled Trials - Obaid OF Fazli
• 'Real world' pembrolizumab in metastatic melanoma - Alexandra E Flynn
• Rare subcutaneous infusion port (SIP) complications in oncology: A case series. - Aaron Gaekwad
• Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). - Mile Janevski
• Nutrition outcomes and toxicities following helical-intensity modulated radiotherapy (H-IMRT) in patients with head and neck cancer - Rainbow Lai
• Nivolumab experience in pre-treated patients with metastatic non-small cell lung cancer (NSCLC) in the Northern Territory. - Corinne Lau Hing Yim
• Trans-arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC): Experience from an Australian tertiary care centre - Minmin Li
• PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis - Georgina Long
• Clinical factors influencing use of Abiraterone and Enzalutamide (A/E) in hormone resistant prostate cancer: real world experience - Andrew Lui
• Updated results from a phase 3 trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067) - Grant McArthur
• A systematic review and Delphi survey of assessment strategies for chemotherapy-induced peripheral neuropathy - J. Matt McCrary
•  Exploring the feasibility of a web-based cognitive rehabilitation intervention for adult cancer survivors: A pilot study - Mary E Mihuta
• The prevalence and clinical implications of complementary and alternative medicine use in oncology patients - Lynn A Nguyen
• Phase I trial of a nanocell packaged microRNA  therapy in malignant pleural mesothelioma (MPM) - Nick Pavlakis
• Screening for Circulating Tumour Cells (CTC) allows early detection of cancer – a cohort study - Karin Ried
• “Big Bang”: Going live on implementation of the Digital Hospital Program in Cancer Services at Princess Alexandra Hospital - Leanne Stone
• Feasability of a retrospective audit of patterns of investigation and treatment for bone complications in patients treated with aromatase inhibitors for early breast cancer - Christina Teng
• Safety Profile of Nivolumab Administered as 30-minute Infusion: Analysis of Data from CheckMate 153 - David Waterhouse
• Outcomes by Site of Metastasis for Patients With Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib Versus Placebo: Results from a Phase 3, Randomized Trial - Louise Young
• Responses in Specific Metastases Following Treatment With Lenvatinib: Results From the Phase 3 SELECT Trial - Louise Young
• Use of Positron Emission Tomography (PET) scan in breast cancer – a single centre study - Hillary Martin
• Vitamin D deficiency and Early Breast Cancer: An Australian experience - Alice RT Bergin
• Cancer Australia Statement – influencing best practice in breast cancer - Briony Jack
• Addressing variations in outcomes for nonmetropolitan and Indigenous women with breast cancer - Kathleen Mahoney
• Understanding the health literacy and information needs of patients newly diagnosed with breast cancer - Bianca Devitt
• A transcriptional signature of TGFβ-induced epithelial mesenchymal transition in cancer - Momeneh Foroutan
• Diary data from the Sexual Activity after Breast Cancer (SAB) Study - Martha Hickey
• Magnetic Resonance Imaging of Mammographic Density - Honor J Hugo
• Clinical practice guidelines for the management of menopausal symptoms in women with a history of breast cancer - Briony Jack
• Optimising Adjuvant Chemotherapy Delivery in Older Women with Breast Cancer - a Review - Timothy S Kalas
• How do average woman think about breast cancer risk and prevention? ‘A huge hot air balloon’ - Kelly A Phillips
• Luminal A Breast Cancer: Australian Regional Cancer Centre Experience   - Hiren Mandaliya
• Men get breast cancer too: a consultation project identifying men’s unmet information and support needs - Pauline McLoughlin
• Contemporary risks of recurrence after adjuvant radiotherapy of patients treated for primary breast cancer - Graham Pitson
• The effect of laterality on rates of cardiac related hospital presentations and admissions following adjuvant radiotherapy for breast cancer - Graham Pitson
• The contribution of routine follow-up to the detection of breast cancer recurrence after treatment for early disease. - Andrew D Redfern
• Coping with personal goal disturbance in the context of breast cancer: key findings and implications - Natalie Stefanic
• Mastectomy Scar Assessment - A review of POSAS Observer Scale - Denise Stewart
• Survival and cardiotoxicity for patients with HER2 positive, metastatic breast cancer treated with trastuzumab in routine clinical practice.   - Anuradha Vasista
• The assessment of testamentary capacity in advanced malignancy - Gauri Gogna
• 24 Hour SAE reporting on Weekends/Public holidays  - Medhia Survery
• High-Cost Medications in Recurrent Glioblastoma Patients - Solving a Hospital Dilemma - Julie Adams
• Biobanking at a Regional Tertiary Hospital: An initial experience and identification of barriers to patient consent - Daniel Brungs
• Avoiding the Emergency Department: a Rapid Assessment & Supportive Care clinic in a busy Australian Cancer Centre - Nikki Burdett
• Cost minimalisation analysis comparing adjuvant radiotherapy with endocrine therapy in elderly patients with oestrogen-receptor positive, low risk, early breast cancer - Ee Siang Choong
• The South Australian Aboriginal Cancer Control Plan 2016-21 and the Value of Partnerships - Tracey Doherty
• Deployment and standardisation of MOSAIQ Medical Oncology in regional centres - Brett J Fielding
• Best practice cancer care in regional Australia initiative - Susan Hanson
• A framework and toolkit for mapping and localising cancer referral and diagnosis pathways - Candice Kielly-Carroll
• Building a web-based system to facilitate health services adherence to the Clinical Pathway for the Identification and Management of Anxiety and Depression in Adult Cancer Patients. - Heather L Shepherd
• The Lymphoedema Clinical Pathway Pilot Project - a community based approach to improve lymphoedema management - Leonie C Naumann
• Early detection of pre-clinical breast cancer related lymphoedema: Is screening using bioimpedance spectroscopy effective? - Sharni Patchell
• Safety audit of accelerated Bevacizumab infusions: a single centre retrospective cohort study - Michael Powell
• A Systematic Review and Meta-Analysis of Patient Reporting Outcomes in Clinical Practice - Natasha Roberts
• Improving methods for the identification of malnutrition in culturally and linguistically diverse patients - Jane Stewart
• The role of cancer care coordinators in Victoria: A mapping project - Rachel Whiffen
• Cross-cultural adaptation of ‘Cancer Care Coordination Questionnaire for Patients’ (CCCQ-P) for Chinese- and Arabic-speaking people - Jane M Young
• Moving Ahead - A group program for women who have completed treatment for breast cancer - Katie Evans
• A Comparison of daily versus intermittent consultant medical oncology ward round: Does daily consultant ward rounds improve length of stay and early discharges? - Wei-Sen Lam
• Commencement of a supervised exercise program for women undergoing treatment for breast cancer and impact on current physiotherapy service provision. - Tara Redemski
• Measuring and improving cancer patients self-efficacy in understanding and using their prescription medication - Kate Witney
• Development and evaluation of patient resources to explain screening for anxiety and depression in cancer care - Heather Shepherd
• Prevalence of breast cancer-related lymphedema after participation in a mulitmodal exercise intervention including heavy resistance training - Kira Bloomquist
• Barriers and Facilitators of exercise experienced by cancer survivors: A mixed methods systematic review - Briana Clifford
• Is bioimpedance spectroscopy the most effective way of screening for lymphoedema following breast cancer? A systematic review. - Sharni Patchell
• A Partnership Providing Sustainable Health Care and Support: The Specialist Cancer Nurse and Expert Peer Support - Leonie Young
• Efficacy of scalp cooling and pharmacokinetics at the Kinghorn Cancer Centre, St Vincent's Hospital - Kate Manollaras
• Predictors of psychological distress amongst outpatient chemotherapy patients: An analysis of depression, anxiety and stress using DASS-21 - Michelle Mcmullen
• Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL) - Paul B Chapman

• Real- time HER2 status monitoring using circulating tumour cells - Ali Asgar Bhagat
• Expression of urokinase plasminogen activation system in primary gastro-oesophageal adenocarcinoma: a systematic review and meta-analysis - Julia Yu Jia Chen
• Broadening the use of the Heng prognostic criteria in metastatic renal cell carcinoma: application of the criteria irrespective of treatment regimen - Brett Hamilton
• A risk score based on preoperative serum metabolomic profiles identifies patients with early breast cancer at increased risk of recurrence in a multicentre population: outcomes by Adjuvant Online stratification. - Christopher D Hart
• Erlotinib survival and use in non-small cell lung cancer at two large Queensland public hospitals: comparison to pivotal trials supporting subsidy on the Pharmaceutical Benefits Scheme - Alexandria McGrath

• Patient Preferences for Adjuvant Radiotherapy - outcomes from the TARGIT-A Study in Western Australia. - Tammy Corica
• Pilot-testing the feasibility and acceptability of a radiation therapy Talking Book - Haryana M Dhillon
• Can exercise prevent aromatase inhibitor (AI) induced musculoskeletal pain in women with breast cancer? An interim report. - Jasotha Sanmugarajah
• Attitudes of patients with metastatic cancer towards research biopsies - Davinia Seah
• Acceptability of tailored life-expectancy information in patients with advanced cancer participating in an Australian nurse-led ACP RCT - Martin HN Tattersall

• Depression and sleep after breast cancer - Helen Proskurin
• Fear of cancer recurrence: how it relates to sleep disturbance and how can we manage it? - Deborah Fenlon
• Managing menopausal symptoms and sleep disturbance after breast cancer - Martha Hickey

5.00 PM  Panel discussion with case studies

• Treatment Focussed Genetic Testing In Women with Breast Cancer – Why Do It? - Kelly-Anne Phillips
• On the Road to Mainstreaming:Genetic Testing for Ovarian Cancer Patients within an Oncology Setting - Maira Kentwell
• ENIGMA quantitative and qualitative classification criteria for evaluating the clinical significance of BRCA1 and BRCA2 sequence variants - Amanda B Spurdle
• Streamlined genetic education is effective in preparing women newly diagnosed with breast cancer for decision-making about treatment-focused genetic testing:  A randomized controlled non-inferiority trial - J Kirk

5:20 PM Panel Discussion

• Liquid Biopsies: Characterising the Cancer Genome in Blood - Sarah-Jane Dawson
• Circulating and disseminated tumour cells in breast cancer - Erik (Rik) Thompson
• Liquid biopsies from solid tumours. - Alexander Dobrovic
• Circulating cell-free tumour DNA in cancer: Post Therapy Monitoring. - Glenn D Francis

• Exploring the rationale, experience and impact of using Cancer Information and Support (CIS) services: An international qualitative study - Anna Boltong
• Radiation therapists providing additional one-on-one education and support sessions prior to radiation therapy reduces patient anxiety - Georgia KB Halkett
• How do I do that again? Vodcasts for patients with feeding tubes and swallowing difficulties  - Nicole Kiss
• Multidisciplinary care for women with Metastatic Breast Cancer (MBC): lessons learned from an implementation study - Mei Krishnasamy
• A Prospective two-year experience of a medical oncology advanced trainee in Queensland - Rahul Ladwa
• Lynch syndrome (LS): an education and support vacuum - Susan Morris

Speaker: Dr Tim Grice

"Are all opioids created equal?… Join us to learn more about Palexia and its role in the treatment of Chronic Cancer Pain"